Potassium voltage-gated channel subfamily Q members 2, 3, 4, and 5 (KCNQ2-5) (KCNQ2-5)

The neuronal KCNQ channel family, comprising subunits KCNQ2 through KCNQ5 (Kv7.2-Kv7.5), plays a critical role in regulating neuronal excitability throughout the central and peripheral nervous systems (UniProt P48522, O43526). These voltage-gated potassium channels are the molecular basis of the M-current, a slow-activating and non-inactivating current that stabilizes the resting membrane potential and limits repetitive firing of action potentials (PubMed: 21106825). KCNQ2 and KCNQ3 subunits often form heterotetramers that dominate the M-current in the brain, while KCNQ4 is predominantly expressed in the inner ear and KCNQ5 is found in both the brain and skeletal muscle (PubMed: 15784753). Mutations in these genes are linked to various channelopathies, most notably Benign Familial Neonatal Seizures (BFNS) and KCNQ2-related developmental and epileptic encephalopathy (PubMed: 25135340). Pharmacologically, these channels are primary targets for anti-seizure medications, where positive allosteric modulators like retigabine enhance channel opening to reduce neuronal firing (StatPearls: Ezogabine). Beyond epilepsy, neuronal KCNQ channels are being investigated as therapeutic targets for neuropathic pain, tinnitus, and mood disorders due to their ability to dampen pathological hyper-excitability. However, achieving subunit selectivity remains a significant challenge to avoid off-target effects, such as the urinary retention and pigmentation issues observed with earlier non-selective activators. Current drug development focuses on next-generation modulators, such as XEN1101 and BHV-7000, with improved potency and safety profiles for refractory epilepsy and other neurological conditions.

Other names

Neuronal Kv7 channelsKv7.2-5M-channel subunitsKQT-like subfamily QVoltage-gated potassium channel subunit Kv7.2/3/4/5

Positive allosteric modulation to increase channel open probability and potassium efflux, thereby hyperpolarizing the membrane; inhibition of the M-current by antagonists to increase excitability for research purposes.